Bando: Cooperation - HEALTH-2013-INNOVATION part 1 (two stage)

Activities/Topics:
1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH
- HEALTH.2013.1.2-1: Development of imaging technologies for therapeutic interventions in rare diseases
- HEALTH.2013.1.3-1: Modelling toxic responses in case studies for predictive human safety assessment
- HEALTH.2013.1.3-2: Innovative approaches to address adverse immune reactions to biomedical devices, implants and transplant tissues
- HEALTH.2013.1.3-3: Safety and efficacy of therapeutic vaccines
- HEALTH.2013.1.3-4: Development of alternative in vitro, analytical, immunochemical, and other test methods for quality control of vaccines
- HEALTH.2013.1.4-1. Controlling differentiation and proliferation in human stem cells intended for therapeutic use
2. TRANSLATING RESEARCH FOR HUMAN HEALTH
- HEALTH.2013.2.1.1-1: Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes
- HEALTH.2013.2.1.1-2: High impact research initiative on metagenomics for personalised medicine approaches
- HEALTH.2013.2.2.1-1: Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI)
- HEALTH.2013.2.2.1-2: Development of effective imaging tools for diagnosis, monitoring and management of mental disorders
- HEALTH.2013.2.2.1-3: Paediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatment
- HEALTH.2013.2.2.1-4: Pathophysiology and therapy of epilepsy and epileptiform disorders
- HEALTH.2013.2.2.1-5: Understanding and controlling pain
- HEALTH.2013.2.3.0-1: Innovation in vaccines
- HEALTH.2013.2.3.1-2: Stratified approaches to antibacterial and/or antifungal treatment
- HEALTH.2013.2.3.3-1: Clinical management of patients in severe epidemics
- HEALTH.2013.2.3.4-1: Neglected infectious diseases of Central and Eastern Europe
- HEALTH.2013.2.3.4-2: Drug development for neglected parasitic diseases
- HEALTH.2013.2.4.1-1: Investigator driven treatment trials to combat or prevent metastases in patients with solid cancer
- HEALTH.2013.2.4.1-2: Strengthening the cancer patient's immune system
- HEALTH.2013.2.4.1-3: Investigator driven   supportive and palliative care clinical trials and observational studies
- HEALTH.2013.2.4.2-1: Discovery research to reveal novel targets for cardiovascular disease treatment
- HEALTH.2013.2.4.2-2: Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases
- HEALTH.2013.2.4.2-3: Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS
- HEALTH.2013.3.1-1: Comparative Effectiveness Research (CER) in health systems and health services interventions
- HEALTH.2013.3.3-1: Social innovation for health promotion
- HEALTH.2013.4.1-1: Supporting industrial participation in EU-funded research in the Health sector
- HEALTH.2013.4.1-2: Interactions between EU legislation and health research and/or innovation and the effects of its application and implementation on health research and/or innovation
- HEALTH.2013.4.1-3: Support for Presidency events: Organisation of supporting actions and events associated to the Presidency of the European Union
- HEALTH.2013.4.1-4: Preparing the future for health research and innovation
- HEALTH.2013.4.1-5: Global initiative on gene-environment interactions in diabetes/obesity in specific populations
- HEALTH.2013.4.1-6: Mapping chronic non-communicable diseases research activities
- HEALTH.2013.4.2-1: Investigator driven clinical trials for off-patent medicines using innovative, age appropriate formulations and/or delivery systems
- HEALTH.2013.4.2-2: Adverse drug reaction research
- HEALTH.2013.4.2-3: New methodologies for clinical trials for small population groups
Per la descrizione dei Topics e dei relativi Funding scheme si rimanda al Work Programme.
REQUISITI DI PARTECIPAZIONE (salvo eccezioni indicate nella Call Fiche):
- COLLABORATIVE PROJECTS: almeno 3 soggetti giuridici indipendenti stabiliti in 3 diversi Stati Membri (MS) o Associati (AC);
- COORDINATION AND SUPPORT ACTIONS (coordinating action): almeno 3 soggetti giuridici indipendenti stabiliti in 3 diversi Stati Membri (MS) o Associati (AC);
- COORDINATION AND SUPPORT ACTIONS (supporting action): almeno un soggetto giuridico
Il Consortium Agreement è obbligatorio per i Collaborative projects.
MODALITA’ DI PRESENTAZIONE: 
Il processo di valutazione delle proposte si svolgerà in 2 fasi.
STAGE 1: le proposte devono essere presentate online attraverso EPSS entro le ore 17.00 del 2 ottobre 2012 (ora di Bruxelles).
STAGE 2: i coordinatori delle proposte selezionate nello stage 1 saranno invitati ad inviare la "full proposal" entro una ulteriore data di scadenza
Call Identifier: FP7-HEALTH-2013-INNOVATION-1
            DOCUMENTI UTILI ALLA PRESENTAZIONE:
- Call Fiche
- Work Programme
- Guide for applicants

Allegati: 

Call Fiche: Cooperation - Bando: Cooperation - HEALTH-2013-INNOVATION part 1 (two stage)